Objectives: To review the current state of development of streptococcus B, herpes-zoster, HIV, malaria and dengue vaccines. These vaccines were selected both because of imminent commercial release and because of specific problems with their development.
Introduction
Five of the innumerable vaccines in development were selected for this review, both because their commercial release is imminent, and because their development presented specific problems. The streptococcus B, herpeszoster, human immunodeficiency virus (HIV), malaria and dengue vaccines were selected because they are all currently in phase III clinical trials. Each of these five diseases represents a significant burden on public health, and each of the vaccines presented development problems that were, and still are, difficult and complex to solve. Some, such as the malaria vaccine, have been in development for decades.
If the results of phase III studies are acceptable, without doubt these vaccines will be available in a short space of time, with the possible exception of the HIV vaccine, which still presents obstacles that will be difficult to overcome.
Streptococcus B vaccine
Invasive disease caused by group B streptococcus (Streptococcus agalactiae, GBS) remains the main cause of death and morbidity among newborn infants (NB) and young children. Group B streptococcus is the main cause of early neonatal bacterial sepsis. 1, 2 Around 80% of infections are acquired during passage through the birth canal. Studies undertaken in the USA identified anogenital colonization by GBS in 25 to 40% of healthy expectant mothers. 3 One of the most effective measures for the prevention of early neonatal bacterial sepsis by GBS was the institution of intrapartum antibiotics, as suggested and recommended by the Centers for Disease Control and Prevention (CDC) since 1996. 4 Despite this recommendation, there are still around 2,500 cases of GBS infection in the USA and approximately 100 deaths each year. 5 The use of intrapartum antibiotics led to a reduction of around 75% in cases of early neonatal bacterial sepsis from GBS, although it has had no influence on the incidence of late sepsis. More than half of the early GBS sepsis cases occur during the first week of life of the NB, with lethality of 25 to 50%. The major issue in the discussions on the use of intrapartum antibiotics for expectant mothers colonized by GBS is the rapid development of GBS strains resistant to penicillin, the drug used for this prophylaxis. 4 It is believed that the development of a vaccine specifically for GBS is the only effective solution for preventing this infection that is so significant, prevalent and lethal among NB, in addition to minimizing impact on the bacterial resistance of the microorganism and possibly avoiding fetal death and prematurity related to this germ.
Development of the vaccine
The rationale behind the development of a vaccine against GBS is that the risk of neonatal GBS infection is inversely proportional to the quantity of maternal antibodies specific to the capsular polysaccharide antigen (CPA) that surrounds GBS. It is believed that the presence of IgG immunoglobulins in the NB is the result of their transplacental passage, conferring temporary protection to the NB. 6 The development of an effective vaccine could theoretically lead to a real reduction in the number of cases of both early and late GBS sepsis.
In 1970, Baker et al. 7 had already predicted the protective action of antibodies to type III CPA of GBS, finding that NB whose mothers had low levels of CPA type III specific antibodies presented increased incidence of early and late invasive GBS disease. Starting from this premise, it is believed that if there were sufficient levels of antibodies in human serum specific to the capsular polysaccharide antigen of GBS, individuals would be protected, since they exhibited adequate opsonization and phagocytosis. It is believed, based on the example of the polysaccharide pneumococcal vaccine, that by developing a vaccine with antibodies to the CPA of GBS for expectant mothers, we would be preventing the disease among NB, by transplacental transfer of protective antibodies. The best time to administer such a vaccine would be during the third trimester of pregnancy, in order to achieve serum antibody levels and transplacental transfer of protection to the NB. The first attempt was a vaccine specific to type III CPA, followed by other attempts with type I and II CPAs (these initial studies achieved immunogenic response in just 40 to 60% of those immunized). 8 Immunoresponse for serotype II was better (88%).
In 1988, Baker et al. developed a vaccination program with pregnant women. Humoral response was 90% for the type III CPA in pregnant women receiving the vaccine during the third trimester of pregnancy, at around week 31, i.e. there was in vitro observation of antibodies in serum from NBs with protective function (opsonization and bacterial death), detected up to 3 months after birth. 9 This was a landmark, demonstrating the real possibility of immunizing the expectant mother and protecting the unborn child from GBS.
Increases have recently been detected in the prevalence rates of invasive disease by GBS from other serotypes than I, II and III, with serotype V being of most concern.
Unfortunately we have little data on the epidemiology and prevalence of the GBS serotypes that cause invasive diseases in Brazil. This epidemiological change raised awareness concerning the need for wider spectrum vaccines, covering many serotypes. It is estimated that a multivalent vaccine covering the serotypes Ia, Ib, II, III and V, could protect against virtually 100% of cases of the disease in infants and adults. 10 The first conjugate vaccine with type III GBS CPA and tetanus toxoid as a carrier protein was developed based on this concept. The results with the new vaccine in expectant mothers demonstrated protection of up to 90% when compared with a placebo group. 11 Since 1996, several new conjugate vaccines specific to the most important serotypes responsible for GBS disease have been tested. In general the vaccines are well tolerated, given to expectant mothers in one or two doses, via intramuscular injection. The most common adverse event is pain and sensitivity at the site of administration. Just 2% of 500 volunteers tested exhibited symptoms, such as low fever, headaches, shivering or myalgia, which resolved in 24 to 48 hours.
The immune response to the different serotypes in the conjugate vaccine is dose-dependent, with the exception of serotype V. Doses such as 4 µg of type II CPA, 10 µg for type V and 15 µg for serotypes Ia, Ib, and III resulted in increases of four times in specific antibody titers in 80 to 93% of the volunteers tested 8 weeks after immunization. Peak antibody levels were detected between 4 and 8 weeks after vaccination, followed by a decrease in levels to the point where, after 1 year, GBSspecific antibody titers had dropped by 50%; however, in common with other conjugate vaccines, protection is maintained for prolonged periods.
The ideal vaccine would be a pentavalent conjugate vaccine. A bivalent combined (II-TT and III-TT) conjugate vaccine has already been developed and tested with good tolerance and immunogenicity. 12 Likewise, for the V serotype, vaccines have already been developed and tested, one conjugated with TT and another with mutant diphtheria toxin (CRM 197 ). 13 Both vaccines were well tolerated and there was no statistically significant difference between them in immunoresponse.
Anything that requires large-scale testing on pregnant women will come up against a debate on scientific ethics. 14 
Herpes-zoster vaccine
Recent studies have demonstrated the efficacy and safety of a herpes-zoster vaccine. 15 It is estimated that around 1 million cases of the disease occur annually in the USA. The importance of this new vaccine is directly related to the probable increase in the incidence of zoster as the decades pass, due to the increased longevity of the population and also to the increasingly frequent use of immunosuppressive drugs and treatments.
Zoster is linked with complications such as postherpetic neuralgia (PHN), herpes ophthalmitis, myocarditis, paresthesias, myopathies and others. The management and treatment of these complications is still far from acceptable.
Epidemiology
The clinical manifestations of latent varicella-zoster virus (VZV) reactivation can occur decades after the primary infection, having a profound effect on the quality of life of patients with the morbidity that is associated with the disease. Epidemiological studies report that the annual incidence of herpes-zoster is 2.9/1,000 in the USA, 16 4.6/1,000 in Iceland, 17 4 .0/1,000 in Italy 18 and 4.8/1,000 in France. 19 There are no Brazilian data since this is not a notifiable disease. In the Italian study, around 50% of cases occurred in individuals over 65 years old, and more than 75% of cases in people over 50 years old.
There is a strong relationship between herpes-zoster incidence and advanced age, reaching figures of 10/ 1,000 per year in the 70 to 80-year-old population. 20 Theoretically, the tendency is for the number of cases to increase, since both longevity and the number of i m m u n o c o m p r o m i s e d p a t i e n t s a r e i n c r e a s i n g .
Management of the disease and its complications still leaves much to be desired. 21 Re-exposure to VZV appears to protect against zoster, whether by contact with infected children with the natural virus or through revaccination. 22 Young adults have CD4 and CD8 memory cells that recognize VZV, making the disease very rare in these immunocompetent individuals.
In immunocompromised patients, loss of VZV-specific T lymphocytes can signify temporary susceptibility to VZV reactivation.
With increasing immunization of children against VZV, there will be reduced circulation of the wild virus in the population, which could lead to an increase in the number of cases of zoster in the elderly population who would no longer be given natural boosters at advanced ages. There are no concrete data on this impact, even for populations with high numbers of children vaccinated against varicella. The use of antivirals in the treatment of acute zoster episodes reduces the duration and extent of the disease, but does not prevent neuralgia.
Development of a new vaccine
The immune status of the elderly, with progressive loss of cell-mediated immunity, predisposes towards VZV infections. The lower the level of cellular immunity, whether due to age or immunosuppressive diseases such as AIDS, the greater the incidence of zoster. In response to these facts, the Shingles Prevention Study ran a large and important project to establish the impact of a zoster vaccine. The objective of the study was to investigate the reduction of pain and discomfort caused by the disease and the impact on its overall incidence in addition to measuring the frequency of complications such as PHN in the elderly population. 26 Oxman et al. conducted the principal study published to date with the zoster vaccine. 26 They worked from the hypothesis that a vaccine against zoster would reduce the incidence and severity of the There was a much larger number of adverse events in the vaccinated group when compared with the placebo group, with local reactions being most common, mostly mild ones.
Future expectations
With the progressive and universal use of the VZV vaccine in children, the circulation of the virus in the wild will probably diminish. The practical implication of this is that the adult population will be exposed to VZV less often and therefore have less opportunities for natural boosters, with resultant lowered cell-based immunity and antibodies specific to VZV.
Another aspect to be highlighted is that life expectancy is in constant expansion. It is estimated that the population over 85 years old in the USA increased by Despite the similarity with infection of monkeys by SIV, this has not proven a practical animal model for studying vaccines. [40] [41] [42] Another subject of investigation are individuals who, despite being exposed to HIV, do not become infected, and also those individuals who, once infected, do not progress to the immunosuppression phase. 
Recombinant vector vaccines
Usually the virus or bacteria used as vector for HIV antigen coding genes will be attenuated or non-pathogenic. Certain genetic variants of each serotype appear to be more virulent or to have greater epidemic potential. 44, 52 Immunity conferred by natural infection is long lasting, but type-specific.
The three-dimensional structure of the E protein consists of a complex dimer with two identical subunits and is subdivided into three distinct domains: 
Malaria vaccines
It is estimated that around 2.7 million people, the majority of them children, die each year from malaria and that more than 2 billion people are exposed to the risk of acquiring the disease worldwide. In Brazil, while the number of deaths may not be excessive, for decades the number of cases has been counted in hundreds of thousands. Malaria, in common with AIDS, has proven an enormous challenge to vaccine development, not just due to the complexity of the immunoresponse to the infection, but also because of a lack of political will. [57] [58] [59] Almost all of the vaccines under development are directed at Plasmodium falciparum, which is responsible for severe forms of malaria and for the vast majority of deaths. 60 Obstacles to developing a vaccine Plasmodium parasites have a complex lifecycle, with many different stages, both within the definitive host and the vector. Different antigens are expressed at different stages in the lifecycle, although the malaria genome project has demonstrated that the same antigen can be expressed at different stages. 61, 62 The major problem, however, is the complexity of the immunoresponse to the parasite. To date, there is no safe and effective vaccine against protozoa, organisms that are infinitely more complex than viruses and bacteria.
Plasmodia have more than 5 thousand genes, as against 5 or 10 in the majority of viruses. [61] [62] [63] Plasmodium spp. and the immunoresponse Sexual phase: some of the merozoites are transformed into male and female gametocytes. These forms may be aspirated once more by the anopheles vector, where they will reproduce sexually, completing the lifecycle by producing sporozoites to be inoculated into another host. 57 The immunoresponse to malaria is partial and both species and strain specific, but there is experimental evidence to demonstrate that a protective vaccine is possible: 64, 65 The immunization of humans and animals with irradiated sporozoites results in partial or complete protection from an experimental infection with viable sporozoites.
Repeated infection leads to natural immunity. Recombinant vector vaccines and DNA vaccines are also being assessed, but it is the subunit vaccines that have advanced furthest. This group can be subdivided according to the phase of the cycle aimed at. 65, 66 Pre-erythrocytic
The best known antigen is the circumsporozoite protein The complete sequencing of the P. falciparum genome has allowed for the identification of potential antigens for investigation. 70 In common with AIDS and dengue, even a partially effective vaccine for malaria would be an advance, since it would reduce transmission, prevent epidemics, reduce the risk of resistance to anti-malarial drugs and, together with mosquito nets impregnated with permetrine and the use of prophylactic medication, could make more effective control possible. 59 
Final comments
This review has demonstrated that the development of a safe and effective vaccine is a process that is long, difficult and, very often, of uncertain success. Of the vaccines described here, it is the one to combat HIV that presents the greatest problems, but the current progress of research permits, perhaps with a little optimism, the prediction that these problems will be overcome in the near future.
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